Sangamo BioSciences Inc. (NASDAQ:SGMO) was downgraded by research analysts at Janney Montgomery Scott from a “buy” rating to a “neutral” rating in a report issued on Thursday. They currently have a $8.00 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $15.00. Janney Montgomery Scott’s price objective indicates a potential […]
